Algert Global’s Viridian Therapeutics VRDN Stock Holding History

Algert Global’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.86M	Sell	482,237 -81,762	-14%	-$1.32M	0.11%	316
2026 Q1	$11M	Buy	563,999 +138,960	+33%	+$4.13M	0.17%	178
2025 Q4	$13.2M	Buy	+425,039	New	+$11.7M	0.21%	130
2025 Q3	–	Sell	-18,693	Closed	-$261K	–	1358
2025 Q2	$261K	Sell	18,693 -26,850	-59%	-$364K	0.01%	1061
2025 Q1	$614K	Sell	45,543 -50,850	-53%	-$866K	0.02%	865
2024 Q4	$1.85M	Sell	96,393 -18,520	-16%	-$403K	0.04%	631
2024 Q3	$2.61M	Buy	114,913 +59,420	+107%	+$971K	0.07%	468
2024 Q2	$722K	Buy	55,493 +17,673	+47%	+$245K	0.02%	771
2024 Q1	$662K	Buy	+37,820	New	+$733K	0.03%	714
2023 Q3	–	Sell	-37,025	Closed	-$881K	–	1265
2023 Q2	$881K	Sell	37,025 -23,523	-39%	-$603K	0.04%	685
2023 Q1	$1.54M	Sell	60,548 -4,705	-7%	-$151K	0.07%	439
2022 Q4	$1.91M	Buy	+65,253	New	+$1.5M	0.11%	314

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Algert Global's VRDN Position: Q2 2026 in Review

Algert Global reduced its Viridian Therapeutics (VRDN) stake by 14% in Q2 2026, selling an estimated $1.32M and leaving 482,237 shares worth $8.86M. The position accounts for 0.11% of the portfolio, ranked #316.

Algert Global first reported a position in VRDN in Q4 2022 and has held it in 12 quarters since. The position peaked at $13.2M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Algert Global held 482,237 shares of Viridian Therapeutics worth $8.86M as of Q2 2026.
Algert Global sold 81,762 Viridian Therapeutics shares in Q2 2026, an estimated $1.32M.
Viridian Therapeutics made up 0.11% of Algert Global's portfolio in Q2 2026, its #316 holding.
Algert Global first reported a position in Viridian Therapeutics in Q4 2022 and has held it in 12 quarters since.
Algert Global's Viridian Therapeutics position peaked at $13.2M in Q4 2025.
212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.